Cargando…
Tolvaptan for Primary Aldosteronism and Autosomal Dominant Polycystic Kidney Disease: A Case Report
A 59-year-old Japanese woman was admitted for evaluation of muscle weakness. Autosomal dominant polycystic kidney disease had been diagnosed at the age of 47 years, followed by primary aldosteronism at 53 years. At the age of 58, tolvaptan was started (60 mg/day) to treat her renal disease. After 8...
Autores principales: | Kunizawa, Kyohei, Hoshino, Junichi, Mizuno, Hiroki, Suwabe, Tatsuya, Sumida, Keiichi, Kawada, Masahiro, Yamanouchi, Masayuki, Sekine, Akinari, Hayami, Noriko, Hiramatsu, Rikako, Hasegawa, Eiko, Sawa, Naoki, Takaichi, Kenmei, Shibata, Shigeru, Ubara, Yoshifumi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5903093/ https://www.ncbi.nlm.nih.gov/pubmed/29692992 http://dx.doi.org/10.1159/000487921 |
Ejemplares similares
-
Tolvaptan for the Treatment of Enlarged Polycystic Liver Disease
por: Mizuno, Hiroki, et al.
Publicado: (2017) -
Denosumab for dialysis patients with osteoporosis: A cohort study
por: Kunizawa, Kyohei, et al.
Publicado: (2020) -
Recurrent Cholangitis in a Patient with Autosomal Dominant Polycystic Kidney Disease (ADPKD) and Caroli's Disease
por: Hasegawa, Eiko, et al.
Publicado: (2016) -
Myeloperoxidase-antineutrophil cytoplasmic antibody-associated crescentic glomerulonephritis in autosomal dominant polycystic kidney disease
por: Sumida, Keiichi, et al.
Publicado: (2013) -
PKD1-associated autosomal dominant polycystic kidney disease with glomerular cysts presenting with nephrotic syndrome caused by focal segmental glomerulosclerosis
por: Oda, Yasuhiro, et al.
Publicado: (2019)